257 related articles for article (PubMed ID: 31133034)
1. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
Zhao Q; Chen G; Ye L; Shi S; Du S; Zeng Z; He J
Radiat Oncol; 2019 May; 14(1):86. PubMed ID: 31133034
[TBL] [Abstract][Full Text] [Related]
2. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
3. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.
Tang C; Liao Z; Gomez D; Levy L; Zhuang Y; Gebremichael RA; Hong DS; Komaki R; Welsh JW
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1084-1091. PubMed ID: 25035212
[TBL] [Abstract][Full Text] [Related]
4. Shortened Radiation Time Promotes Recovery From Radiation-induced Lymphopenia in Early-Stage Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Zhao Q; Li T; Du S; He J; Zeng Z
Technol Cancer Res Treat; 2022; 21():15330338221112287. PubMed ID: 35816375
[No Abstract] [Full Text] [Related]
5. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer.
Campian JL; Ye X; Brock M; Grossman SA
Cancer Invest; 2013 Mar; 31(3):183-8. PubMed ID: 23432821
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
8. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.
Cho Y; Park S; Byun HK; Lee CG; Cho J; Hong MH; Kim HR; Cho BC; Kim S; Park J; Yoon HI
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1065-1073. PubMed ID: 31476418
[TBL] [Abstract][Full Text] [Related]
9. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
10. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
Hoffmann M; Reitz D; Taugner J; Roengvoraphoj O; Käsmann L; Eze C; Karin M; Belka C; Manapov F
Anticancer Res; 2020 Apr; 40(4):2319-2322. PubMed ID: 32234932
[TBL] [Abstract][Full Text] [Related]
11. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer.
Chen M; Jiang GL; Fu XL; Wang LJ; Qian H; Chen GY; Zhao S; Liu TF
Lung Cancer; 2000 Apr; 28(1):11-9. PubMed ID: 10704704
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer.
Sigel K; Lurslurchachai L; Bonomi M; Mhango G; Bergamo C; Kale M; Halm E; Wisnivesky J
Lung Cancer; 2013 Nov; 82(2):266-70. PubMed ID: 24011407
[TBL] [Abstract][Full Text] [Related]
13. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
14. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
[No Abstract] [Full Text] [Related]
16. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
[TBL] [Abstract][Full Text] [Related]
17. Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
Sampath S; Hall M; Schultheiss TE
Lung Cancer; 2015 Oct; 90(1):61-4. PubMed ID: 26231092
[TBL] [Abstract][Full Text] [Related]
18. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
20. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
